Sturge-Weber syndrome

Definition and phenotype

The classic teaching pattern is facial PWB, leptomeningeal capillary-venous malformation and ocular vascular disease such as glaucoma or diffuse choroidal haemangioma. Expression is incomplete: intracranial SWS can occur without a facial PWB, and an isolated PWB is not SWS. The condition is not a germline Mendelian phakomatosis.[2][4][6]

Historical Roach shorthand

[5] [6]

Roach I–III is useful historical exam shorthand, not a validated diagnostic or screening rule. Modern assessment is phenotype-led.[5][6]

Who is at higher risk?

Risk is better predicted by forehead, median, hemifacial or extensive segmental PWB than by assigning a trigeminal branch. A practical high-risk forehead territory extends from the midline laterally toward a line joining the outer canthus and top of the ear and includes the upper eyelid. Any eyelid/periocular PWB, including lower-eyelid involvement, increases glaucoma concern. A nuchal salmon patch or a small isolated lower-face stain does not carry the same pattern of risk.[2][5][7]

Genetics and pathophysiology

Most SWS and many isolated PWBs carry a post-zygotic activating GNAQ p.Arg183Gln (R183Q) variant in affected tissue. Rare mosaic GNA11 variants produce an overlapping phenotype. Variant burden varies across skin, brain and eye; a negative blood test does not exclude tissue mosaicism.[1][16]

Altered Gαq/Gα11 signalling and abnormal vessel maturation are implicated, but the complete downstream chain from mosaic variant to each phenotype remains unsettled. In the brain, leptomeningeal vascular malformation impairs superficial venous drainage; collateral deep veins, chronic hypoperfusion, cortical atrophy, gliosis and gyriform calcification may develop. In the eye, angle dysgenesis and elevated episcleral venous pressure contribute differently by age.[1][4][6]

Clinical presentation

Skin

A PWB is a flat pink-red congenital capillary malformation. It persists and grows proportionately, often darkening, thickening or becoming nodular with age. It is not an infantile haemangioma, which usually appears after birth, proliferates and later involutes. Extensive lesions may accompany soft-tissue or bony overgrowth and mucosal involvement.[3][5]

Neurological

Focal seizures often begin in infancy but may begin later. Other manifestations include status epilepticus, headache or migraine, stroke-like episodes, visual-field loss, developmental/cognitive or behavioural difficulties and transient or permanent hemiparesis. A unilateral cerebral lesion typically causes a contralateral motor deficit. Earlier seizure onset, greater seizure burden and bilateral or extensive brain involvement are associated with poorer outcomes; this association does not prove that any single prophylactic treatment prevents disability.[4][6][12]

Eye

Glaucoma may present in infancy or later life. Infant clues include increasing corneal diameter or globe size, corneal haze, photophobia and tearing. Diffuse choroidal haemangioma may cause refractive error, amblyopia, visual-field loss or serous retinal detachment. Preventable visual loss is why referral should not wait for symptoms.[2][6]

Endocrine associations

Small older cohorts reported growth-hormone deficiency and central hypothyroidism in SWS. Plot linear growth and evaluate for growth-hormone deficiency if growth falters. One centre identified central hypothyroidism in 2 of 83 patients with SWS and brain involvement and recommended routine thyroid-function testing, especially when clinical manifestations are present. Neither report establishes a universal multi-hormone screening panel.[18][19]

Differential diagnosis

Other mimics depend on presentation: PHACE has a large segmental infantile haemangioma rather than PWB; Klippel–Trenaunay syndrome combines limb capillary/venous malformation with overgrowth; tuberous sclerosis and focal cortical dysplasia enter the epilepsy differential; meningitis, infarction and other causes must be considered during an acute deficit.[5][6]

Assessment and investigations

At first recognition of a high-risk PWB

1. Map and photograph forehead, both eyelids, cheek, lip, midline crossing and mucosal involvement.
2. Arrange prompt baseline paediatric ophthalmology and periodic individualized follow-up for eyelid/periocular PWB or known SWS.
3. Arrange paediatric neurology baseline assessment and periodic clinical follow-up; teach caregivers how focal seizures may look.
4. Record development, head growth, motor asymmetry and visual behaviour.[2][5][7]

Brain imaging: the examinable distinction

• Asymptomatic high-risk infant: routine screening MRI is not recommended by the 2021 consensus. Imaging is a specialist-led, shared decision for selected cases, such as subtle symptoms, extensive/bilateral PWB or consideration of presymptomatic therapy. Early MRI can be falsely negative; reported retrospective false-negative rates are 3–23%.[2][8][9]
• If selective presymptomatic screening is chosen: a fast, non-sedated, non-contrast protocol including T1/T2 or FLAIR and SWI may reduce anaesthesia and gadolinium exposure; local paediatric neuroradiology expertise matters.[2][10]
• After a seizure, focal deficit or other neurological symptom: obtain optimized MRI before and after contrast, including SWI and appropriate vascular/parenchymal sequences. CT may show gyriform “tram-track” calcification but is not routine first-line imaging in a child.[2][4][10]
• Stable established SWS: routine serial MRI is not recommended. Repeat imaging is symptom-triggered or used for presurgical planning.[2]

EEG evaluates suspected seizures and supports epilepsy management. Baseline or quantitative EEG may show asymmetry in some asymptomatic infants, but EEG is neither diagnostic nor a rule-out test; a normal study does not exclude later seizures or brain involvement.[2][11]

Management

Acute seizure or new deficit

During a prolonged convulsive seizure, follow an age-appropriate status pathway: airway/breathing/circulation, oxygen if needed, bedside glucose, prompt rescue benzodiazepine, second-line antiseizure medication per local paediatric protocol, and anaesthesia/PICU escalation for refractory status. Treat fever and dehydration and avoid hypotension. Do not delay seizure treatment for imaging.[13]

A new persistent focal deficit, prolonged non-resolving stroke-like episode, atypical severe headache or failure to recover as expected requires urgent neurology reassessment and symptom-directed MRI. Transient peri-ictal imaging abnormalities can occur; SWS stroke-like episodes are not automatically arterial thromboembolic stroke.[2][4]

Long-term neurological care

Use standard antiseizure medications after epilepsy develops, individualized to seizure type, age, comorbidity and interaction profile. Drug-resistant unilateral disease warrants early assessment in a specialist paediatric epilepsy-surgery centre; hemispherectomy/hemispherotomy or posterior resection depends on anatomical extent and preserved function.[2][4]

Aspirin and presymptomatic therapy require an uncertainty statement. Low-dose aspirin 3–5 mg/kg/day has been used off-label in specialist centres for SWS brain involvement, supported by retrospective cohorts rather than randomized trials; bruising and bleeding require counselling and paediatric viral-illness precautions follow local policy. A very small retrospectively matched study of presymptomatic aspirin with or without antiseizure medication generated a hypothesis, not proof of prevention or a universal standard.[14][15]

Ophthalmic care

Care is age- and phenotype-specific. Infantile/early-onset glaucoma frequently requires surgery because developmental angle abnormality contributes; later-onset disease may begin with pressure-lowering medication, with angle, filtering or drainage-device procedures individualized. Lifelong periodic monitoring is needed because glaucoma can present late. Choroidal haemangioma complications need retina expertise.[2][6]

Cutaneous and supportive care

Pulsed-dye laser (PDL) is first-line for lightening facial PWB. It usually requires multiple sessions; complete clearance is uncommon and recurrence or later darkening can occur. Earlier treatment may improve feasibility and lightening, but evidence does not establish prevention of hypertrophy. Anaesthesia decisions are individualized; selected infants can be treated without general anaesthesia.[3][5][17]

Developmental, physiotherapy, occupational, speech, school and psychological supports should match the child’s phenotype. Visible difference, repeated procedures, epilepsy and cognitive symptoms affect both patient and family; shared decision-making includes the option to defer cosmetic treatment.[2][6]

Counselling, prognosis and follow-up

The mutation is usually post-zygotic and tissue-limited, so typical SWS is not inherited in a Mendelian pattern and sibling recurrence is expected to be extremely low rather than mathematically zero. Offer genetics review for atypical, bilateral, extensive or apparently familial presentations. A negative blood assay cannot exclude mosaicism in affected tissue.[1][16]

Outcome varies with brain involvement, seizure onset/burden, bilateral disease, vision and access to supportive care. Follow-up is clinical and phenotype-led: neurology and development, individualized lifelong eye surveillance, dental/soft-tissue review when involved, and symptom-triggered rather than routine serial neuroimaging.[2][4][12]

[2] [5] [8]

Exam core

[2] [4] [14] [15]

Key takeaways

1. SWS is a variable sporadic mosaic disorder, not a required triad and not a Mendelian syndrome.
2. GNAQ p.Arg183Gln is most common; rare GNA11 mosaicism overlaps, and downstream mechanisms remain incomplete.
3. Forehead/median/extensive PWB predicts brain risk; any eyelid/periocular involvement raises glaucoma concern.
4. Routine MRI is not recommended for every asymptomatic high-risk infant; specialist-selected screening and post-symptomatic diagnostic MRI are different decisions.
5. Management is phenotype-led: acute seizure care, individualized epilepsy and glaucoma treatment, repeated PDL sessions, and transparent uncertainty around aspirin/presymptomatic therapy.[1][2][3][16]

References

1. [1]Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med, 2013.PMID 23656586
2. [2]Sabeti S, Ball KL, Bhattacharya SK, et al. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. Pediatr Neurol, 2021.PMID 34153815
3. [3]Sabeti S, Ball KL, Burkhart C, et al. Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. JAMA Dermatol, 2021.PMID 33175124
4. [4]Yeom S, Comi AM. Updates on Sturge-Weber Syndrome. Stroke, 2022.PMID 36263782
5. [5]Poliner A, Fernandez Faith E, Blieden L, et al. Port-wine Birthmarks: Update on Diagnosis, Risk Assessment for Sturge-Weber Syndrome, and Management. Pediatr Rev, 2022.PMID 36045161
6. [6]Ramirez EL, Jülich K. Sturge-Weber syndrome: an overview of history, genetics, clinical manifestations, and management. Semin Pediatr Neurol, 2024.PMID 39389653
7. [7]Waelchli R, Aylett SE, Robinson K, et al. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. Br J Dermatol, 2014.PMID 24976116
8. [8]Zallmann M, Leventer RJ, Mackay MT, et al. Screening for Sturge-Weber syndrome: A state-of-the-art review. Pediatr Dermatol, 2018.PMID 29034507
9. [9]Zallmann M, Mackay MT, Leventer RJ, et al. Retrospective review of screening for Sturge-Weber syndrome with brain magnetic resonance imaging and electroencephalography in infants with high-risk port-wine stains. Pediatr Dermatol, 2018.PMID 30020536
10. [10]Hu J, Yu Y, Juhasz C, et al. MR susceptibility weighted imaging (SWI) complements conventional contrast enhanced T1 weighted MRI in characterizing brain abnormalities of Sturge-Weber Syndrome. J Magn Reson Imaging, 2008.PMID 18666142
11. [11]Ewen JB, Kossoff EH, Crone NE, et al. Use of quantitative EEG in infants with port-wine birthmark to assess for Sturge-Weber brain involvement. Clin Neurophysiol, 2009.PMID 19589723
12. [12]Luat AF, Behen ME, Chugani HT, et al. Cognitive and motor outcomes in children with unilateral Sturge-Weber syndrome: Effect of age at seizure onset and side of brain involvement. Epilepsy Behav, 2018.PMID 29414553
13. [13]Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr, 2016.PMID 26900382
14. [14]Day AM, Hammill AM, Juhász C, et al. Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset. Pediatr Neurol, 2019.PMID 30482419
15. [15]Lance EI, Sreenivasan AK, Zabel TA, et al. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol, 2013.PMID 23112247
16. [16]Polubothu S, Al-Olabi L, Carmen Del Boente M, et al. GNA11 Mutation as a Cause of Sturge-Weber Syndrome: Expansion of the Phenotypic Spectrum of G(α/11) Mosaicism and the Associated Clinical Diagnoses. J Invest Dermatol, 2020.PMID 31838126
17. [17]Jeon H, Bernstein LJ, Belkin DA, et al. Pulsed Dye Laser Treatment of Port-Wine Stains in Infancy Without the Need for General Anesthesia. JAMA Dermatol, 2019.PMID 30865245
18. [18]Miller RS, Ball KL, Comi AM, et al. Growth hormone deficiency in Sturge-Weber syndrome. Arch Dis Child, 2006.PMID 16551788
19. [19]Comi AM, Bellamkonda S, Ferenc LM, et al. Central hypothyroidism and Sturge-Weber syndrome. Pediatr Neurol, 2008.PMID 18555176